{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:44Z","timestamp":1790168444674,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04325-5","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:53:24Z","timestamp":1777096404000},"page":"4297-4307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-1\u03b1 (IL-1\u03b1) in pancreatic ductal adenocarcinoma: implications for immunotherapy and molecular biomarkers"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1870-3802","authenticated-orcid":false,"given":"Ke","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxu","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"4325_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"issue":"7","key":"4325_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493\u2013502.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4325_CR3","volume-title":"Cancer facts & figures 2025","author":"American Cancer Society","year":"2025","unstructured":"American Cancer Society. Cancer facts & figures 2025. Atlanta: American Cancer Society; 2025."},{"key":"4325_CR4","doi-asserted-by":"crossref","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.","DOI":"10.1038\/nrdp.2016.22"},{"issue":"6","key":"4325_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"JP Neoptolemos","year":"2023","unstructured":"Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2023;20(6):388\u2013404.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"4325_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3748\/wjg.v18.i12.1286","volume":"18","author":"M Herreros-Villanueva","year":"2012","unstructured":"Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Mouse models of pancreatic cancer. World J Gastroenterol. 2012;18(12):1286\u201394.","journal-title":"World J Gastroenterol"},{"issue":"7681","key":"4325_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran VP, \u0141uksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512\u20136.","journal-title":"Nature"},{"issue":"26","key":"4325_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"9","key":"4325_CR9","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.4049\/jimmunol.2001342","volume":"206","author":"CB Haas","year":"2021","unstructured":"Haas CB, Lov\u00e1szi M, Braganhol E, Pacher P, Hask\u00f3 G. Ectonucleotidases in inflammation, immunity, and cancer. J Immunol. 2021;206(9):1983\u201390.","journal-title":"J Immunol"},{"issue":"6","key":"4325_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39(6):1003\u201318.","journal-title":"Immunity"},{"issue":"1","key":"4325_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8\u201327.","journal-title":"Immunol Rev"},{"issue":"3","key":"4325_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030744","volume":"14","author":"Y Sunami","year":"2022","unstructured":"Sunami Y, H\u00e4u\u00dfler J, Zourelidis A, Kleeff J. Cancer-associated fibroblasts and tumor cells in pancreatic cancer microenvironment and metastasis: paracrine regulators, reciprocation and exosomes. Cancers (Basel). 2022;14(3):744.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4325_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","volume":"14","author":"S Xiong","year":"2021","unstructured":"Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4325_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"1","key":"4325_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s13256-025-05302-2","volume":"19","author":"KVC Chow","year":"2025","unstructured":"Chow KVC, Mui K, Hunt S, Gan CL. Treatment-refractory immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in the setting of adjuvant pembrolizumab for resected stage IIC melanoma: a case report. J Med Case Rep. 2025;19(1):535.","journal-title":"J Med Case Rep"},{"issue":"4","key":"4325_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500\u20133.","journal-title":"Nat Med"},{"issue":"12","key":"4325_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"27","key":"4325_CR18","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3748\/wjg.v28.i27.3297","volume":"28","author":"C Smith","year":"2022","unstructured":"Smith C, Zheng W, Dong J, Wang Y, Lai J, Liu X, et al. Tumor microenvironment in pancreatic ductal adenocarcinoma: implications in immunotherapy. World J Gastroenterol. 2022;28(27):3297\u2013313.","journal-title":"World J Gastroenterol"},{"key":"4325_CR19","doi-asserted-by":"crossref","unstructured":"Cheng Y, Xiao S, Li X, Wang B, Lei Y, Sun P, et al. Interleukin family-based signature relates to cancer-associated fibroblasts and prognosis in pancreatic carcinoma. Front Oncol. 2025;15:1231883.","DOI":"10.2147\/JIR.S532651"},{"key":"4325_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fimmu.2013.00177","volume":"4","author":"E Voronov","year":"2013","unstructured":"Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, et al. Unique versus redundant functions of IL-1\u03b1 and IL-1\u03b2 in the tumor microenvironment. Front Immunol. 2013;4:177.","journal-title":"Front Immunol"},{"key":"4325_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-12-20","volume":"12","author":"D Basso","year":"2014","unstructured":"Basso D, Bozzato D, Padoan A, Moz S, Zambon CF, Fogar P, et al. Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGF\u03b21. Cell Commun Signal. 2014;12:20.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"4325_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152822","volume":"229","author":"A Miraki Feriz","year":"2024","unstructured":"Miraki Feriz A, Khosrojerdi A, Erfanian N, Azarkar S, Sajjadi SM, Shojaei MJ, et al. Targeting the dynamic transcriptional landscape of Treg subpopulations in pancreatic ductal adenocarcinoma: Insights from single-cell RNA sequencing analysis with a focus on CTLA4 and TIGIT. Immunobiology. 2024;229(4):152822.","journal-title":"Immunobiology"},{"issue":"6","key":"4325_CR23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878\u201385.","journal-title":"Nat Med"},{"issue":"1","key":"4325_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1186\/s12967-025-06744-4","volume":"23","author":"Y Li","year":"2025","unstructured":"Li Y, Wang L, Ma W, Wu J, Wu Q, Sun C. Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment. J Transl Med. 2025;23(1):697.","journal-title":"J Transl Med"},{"issue":"4","key":"4325_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4325_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/587250","volume":"2015","author":"AS Gerdtsson","year":"2015","unstructured":"Gerdtsson AS, Malats N, S\u00e4ll A, Real FX, Porta M, Skoog P, et al. A Multicenter trial defining a serum protein signature associated with pancreatic ductal adenocarcinoma. Int J Proteomics. 2015;2015:587250.","journal-title":"Int J Proteomics"},{"issue":"1","key":"4325_CR27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-020-00385-3","volume":"5","author":"A Weber","year":"2020","unstructured":"Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Signal Transduct Target Ther. 2020;5(1):263.","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"4325_CR28","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.18632\/oncotarget.2624","volume":"5","author":"L Prabhu","year":"2014","unstructured":"Prabhu L, Mundade R, Korc M, Loehrer PJ, Lu T. Critical role of NF-\u03baB in pancreatic cancer. Oncotarget. 2014;5(22):10969\u201375.","journal-title":"Oncotarget"},{"issue":"7769","key":"4325_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-019-1510-8","volume":"572","author":"G Biffi","year":"2019","unstructured":"Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Nature. 2019;572(7769):524\u201330. https:\/\/doi.org\/10.1038\/s41586-019-1510-8.","journal-title":"Nature"},{"key":"4325_CR30","doi-asserted-by":"crossref","unstructured":"Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK\/STAT signalling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282\u2013301.","DOI":"10.1158\/2159-8290.CD-18-0710"},{"issue":"1","key":"4325_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12967-025-06778-8","volume":"23","author":"Q Li","year":"2025","unstructured":"Li Q, Yang C, Li J, Wang R, Min J, Song Y, et al. The type I collagen paradox in PDAC progression: microenvironmental protector turned tumor accomplice. J Transl Med. 2025;23(1):406.","journal-title":"J Transl Med"},{"issue":"1","key":"4325_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-025-00683-x","volume":"26","author":"F Liu","year":"2025","unstructured":"Liu F, Yin P, Jiao B, Shi Z, Qiao F, Xu J. Detecting the preoperative peripheral blood systemic immune-inflammation index (SII) as a tool for early diagnosis and prognosis of gallbladder cancer. BMC Immunol. 2025;26(1):7.","journal-title":"BMC Immunol"},{"key":"4325_CR33","unstructured":"Du H, Si G, Si J, Song X, Si F. Integration of single-cell RNA and bulk RNA sequencing revealed a CTSV-based signature for predicting prognosis and immunotherapy response in pancreatic adenocarcinoma. Front Oncol. 2025;15:1523456."},{"issue":"6","key":"4325_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2016.03.009","volume":"37","author":"M H\u00f6lzel","year":"2016","unstructured":"H\u00f6lzel M, T\u00fcting T. Inflammation-induced plasticity in melanoma therapy and metastasis. Trends Immunol. 2016;37(6):364\u201374.","journal-title":"Trends Immunol"},{"issue":"11","key":"4325_CR35","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau C, Cao J, Gong D, Gregory MT, Caldwell NJ, Yin X, et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat Genet. 2024;56(11):2466\u201378.","journal-title":"Nat Genet"},{"key":"4325_CR36","unstructured":"Mirlekar B, Michaud D, Lee SJ, Kren NP, Harris C, Greene K, et al. B cell-derived IL-35 drives STAT3-dependent CD8+ T-cell exclusion in pancreatic cancer. Cancer Immunol Res. 2025;13(4):456\u201368."},{"issue":"6","key":"4325_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061216","volume":"12","author":"L Gigante","year":"2024","unstructured":"Gigante L, Gaudilli\u00e8re-Le Dain G, Bertaut A, Truntzer C, Ghiringhelli F. Interleukin-1\u03b1 as a potential prognostic biomarker in pancreatic cancer. Biomedicines. 2024;12(6):1216.","journal-title":"Biomedicines"},{"issue":"1","key":"4325_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0400-5","volume":"35","author":"V Tjomsland","year":"2016","unstructured":"Tjomsland V, Sandnes D, Pomianowska E, Cizmovic ST, Aasrum M, Brusevold IJ, et al. The TGF\u03b2-SMAD3 pathway inhibits IL-1\u03b1 induced interactions between human pancreatic stellate cells and pancreatic carcinoma cells and restricts cancer cell migration. J Exp Clin Cancer Res. 2016;35(1):122.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"4325_CR39","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/cac2.12584","volume":"44","author":"Z Xin","year":"2024","unstructured":"Xin Z, Qin L, Tang Y, Guo S, Li F, Fang Y, et al. Immune mediated support of metastasis: implication for bone invasion. Cancer Commun. 2024;44(9):967\u201391.","journal-title":"Cancer Commun"},{"issue":"2","key":"4325_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3978\/j.issn.2078-6891.2012.021","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105\u201319. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2012.021.","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"4325_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1593\/neo.11332","volume":"13","author":"V Tjomsland","year":"2011","unstructured":"Tjomsland V, Sp\u00e5ngeus A, V\u00e4lil\u00e4 J, Sandstr\u00f6m P, Borch K, Druid H, et al. Interleukin 1\u03b1 sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia. 2011;13(8):664\u201375.","journal-title":"Neoplasia"},{"key":"4325_CR42","doi-asserted-by":"crossref","unstructured":"Ohara Y, Liu H, Moreno P, Suzuki S, Hussain SP. Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma: implications for precision therapy. Pharmacol Ther. 2025;1(277):108946.","DOI":"10.1016\/j.pharmthera.2025.108946"},{"issue":"6","key":"4325_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"key":"4325_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.semcancer.2025.02.009","volume":"111","author":"K Murray","year":"2025","unstructured":"Murray K, Oldfield L, Stefanova I, Gentiluomo M, Aretini P, O\u2019Sullivan R, et al. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Semin Cancer Biol. 2025;111:76\u201388.","journal-title":"Semin Cancer Biol"},{"issue":"7592","key":"4325_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47\u201352.","journal-title":"Nature"},{"issue":"10","key":"4325_CR46","first-page":"1048","volume":"5","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor-specific subtypes of pancreatic ductal adenocarcinoma. Cancer Discov. 2015;5(10):1048\u201361.","journal-title":"Cancer Discov"},{"issue":"8","key":"4325_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070874","volume":"8","author":"V Tjomsland","year":"2013","unstructured":"Tjomsland V, Bojmar L, Sandstr\u00f6m P, Bratth\u00e4ll C, Messmer D, Sp\u00e5ngeus A, et al. IL-1\u03b1 expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway. PLoS ONE. 2013;8(8):e70874.","journal-title":"PLoS ONE"},{"issue":"1","key":"4325_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07346-7","volume":"20","author":"X Jin","year":"2020","unstructured":"Jin X, Dai L, Ma Y, Wang J, Yan H, Jin Y, et al. Homeobox proteins are potential biomarkers and therapeutic targets in gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):866.","journal-title":"BMC Cancer"},{"issue":"1","key":"4325_CR49","doi-asserted-by":"publisher","first-page":"29733","DOI":"10.1038\/s41598-025-12651-x","volume":"15","author":"L Liang","year":"2025","unstructured":"Liang L, Zhou Y, Zhang Y, Ou S, Yuan Z, Yi H, et al. The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome. Sci Rep. 2025;15(1):29733.","journal-title":"Sci Rep"},{"issue":"10","key":"4325_CR50","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3389\/fimmu.2019.01197","volume":"7","author":"KJ Baker","year":"2019","unstructured":"Baker KJ, Houston A, Brint E. IL-1 family members in cancer; two sides to every story. Front Immunol. 2019;7(10):1197.","journal-title":"Front Immunol"},{"issue":"1","key":"4325_CR51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41467-023-44363-z","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Byrne KT, Yan F,\nYuan X, Pu X, Huang Y, et al. Tumor cell-intrinsic metabolic reprogramming induces EMT and immune evasion in metastatic PDAC. Nat Commun. 2024;15(1):229.","journal-title":"Nat Commun"},{"key":"4325_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1477-7819-11-219","volume":"11","author":"R Que","year":"2013","unstructured":"Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol. 2013;11:219.","journal-title":"World J Surg Oncol"},{"issue":"10","key":"4325_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.38031","volume":"8","author":"I Stefanova","year":"2025","unstructured":"Stefanova I, Thompson N, Oldfield L, Stott M, Hanson R, Palmer D, et al. Cost-effectiveness of biomarker-associated early pancreatic cancer detection in new-onset diabetes. JAMA Netw Open. 2025;8(10):e2538031.","journal-title":"JAMA Netw Open"},{"key":"4325_CR54","doi-asserted-by":"crossref","unstructured":"Singh G, Kutcher D, Lally R, Rai V. Targeting neoantigens in pancreatic ductal adenocarcinoma: from bench to bedside. Cancers (Basel). 2024;16(11):2045.","DOI":"10.3390\/cancers16112101"},{"key":"4325_CR55","unstructured":"Zhang J, Xiao L, Zhang Y, Jin G, Zheng K. AI-powered vaccine breakthroughs: targeting pancreatic cancer neoantigens with machine learning-optimized mRNA platforms. J Clin Oncol. 2025;43(28):4567\u201378."},{"key":"4325_CR56","doi-asserted-by":"crossref","unstructured":"Li H, Liu D, Li K, Wang Y, Zhang G, Qi L, et al. Pancreatic stellate cells and the interleukin family: implications for fibrosis and therapy in pancreatic cancer. Mol Med Rep. 2024;30(2):13283.","DOI":"10.3892\/mmr.2024.13283"},{"issue":"1","key":"4325_CR57","first-page":"2","volume":"24","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2012;24(1):2\u20138.","journal-title":"Semin Immunol"},{"key":"4325_CR58","doi-asserted-by":"crossref","unstructured":"Nissen NI, Hansen N, Gyllenb\u00e4ck EJ, Millrud CR, J\u00e4r\u00e5s M, Liberg D, et al. IL1RAP blockade mediates anti-fibrotic effects in pancreatic cancer-associated fibroblasts. Nordic Bioscience Preclinical Report. 2024.","DOI":"10.1158\/1538-7445.AM2024-2895"},{"key":"4325_CR59","doi-asserted-by":"crossref","unstructured":"Mohammed N, Jackson RW, Lee SI, Gummeson J. IBID: Intra-body identification using capacitive backscatter. IEEE Int Conf RFID Technol Appl. 2024. p. 54\u201357.","DOI":"10.1109\/RFID-TA64374.2024.10965181"},{"issue":"1","key":"4325_CR60","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1038\/s41467-018-06949-w","volume":"9","author":"CKM Ip","year":"2018","unstructured":"Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, Leonard PG, et al. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nat Commun. 2018;9(1):4583.","journal-title":"Nat Commun"},{"issue":"1","key":"4325_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12967-019-1782-x","volume":"17","author":"K Zhang","year":"2019","unstructured":"Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019;17(1):30.","journal-title":"J Transl Med"},{"key":"4325_CR62","doi-asserted-by":"crossref","unstructured":"Zhang T, Ren Y, Yang P, Wang J, Zhou H. Metabolic and immune crosstalk between cancer-associated fibroblasts and tumor cells in pancreatic ductal adenocarcinoma. J Transl Med. 2025;23:716.","DOI":"10.1186\/s12967-025-07164-0"},{"issue":"8","key":"4325_CR63","first-page":"1044","volume":"12","author":"A Morgan","year":"2023","unstructured":"Morgan A, Griffin M, Kameni L, Wan DC, Longaker MT, Norton JA. Medical biology of cancer-associated fibroblasts in pancreatic cancer. Biology (Basel). 2023;12(8):1044.","journal-title":"Biology (Basel)"},{"issue":"6024","key":"4325_CR64","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612\u20136.","journal-title":"Science"},{"issue":"10105","key":"4325_CR65","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833\u201342.","journal-title":"Lancet"},{"key":"4325_CR66","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.23.639774","author":"A Boda","year":"2025","unstructured":"Boda A, Bandey IN, Chowdhury S, Aggarwal S, Venugopala M, Fowlkes NW, et al. IL-1R1 blockade boosts CD40 agonist immune responses but fails to improve efficacy or reduce hepatotoxicity in pancreatic cancer. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.02.23.639774.","journal-title":"bioRxiv"},{"issue":"43","key":"4325_CR67","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"4325_CR68","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinsk\u00e1 E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998\u20131013.","journal-title":"Cancer Discov"},{"key":"4325_CR69","doi-asserted-by":"crossref","unstructured":"Bandey I,\nBoda A,\nChowdhury S,\nRoszik J,\nMorris V,\nKopetz S,\net al. Enhancing CD40 agonist efficacy and reducing toxicity in pancreatic cancer through IL-1 pathway blockade. J Immunother Cancer. 2024;12(Suppl 2):A819.","DOI":"10.1136\/jitc-2024-SITC2024.0717"},{"issue":"9","key":"4325_CR70","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/2326-6066.CIR-23-1073","volume":"12","author":"PE Oberstein","year":"2024","unstructured":"Oberstein PE, Dias Costa A, Kawaler EA, Cardot-Ruffino V, Rahma OE, Beri N, et al. Blockade of IL1\u03b2 and PD1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor. Cancer Immunol Res. 2024;12(9):1221\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"18","key":"4325_CR71","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","volume":"27","author":"B Bockorny","year":"2021","unstructured":"Bockorny B, Macarulla T, Semenisty V, Borazanci E, Feliu J, Ponz-Sarvise M, et al. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 Trial. Clin Cancer Res. 2021;27(18):5020\u20137.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"4325_CR72","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1158\/1078-0432.CCR-24-0645","volume":"30","author":"E Van Cutsem","year":"2024","unstructured":"Van Cutsem E, Collignon J, Eefsen RL, Ochsenreither S, Zvirbule Z, Ivanauskas A, et al. Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced\/metastatic pancreatic cancer. Clin Cancer Res. 2024;30(23):5293\u2013303.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4325_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009523","volume":"12","author":"N Hansen","year":"2024","unstructured":"Hansen N, Pe\u00f1a-Mart\u00ednez P, Skoog P, Reinbach K, Hansen FC, Faria SL, et al. Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment. J Immunother Cancer. 2024;12(12):e009523.","journal-title":"J Immunother Cancer"},{"key":"4325_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100789","volume":"28","author":"K Herremans","year":"2022","unstructured":"Herremans KM, Szymkiewicz DD, Riner AN, Bohan RP, Tushoski GW, Davidson AM, et al. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Neoplasia. 2022;28:100282.","journal-title":"Neoplasia"},{"issue":"1","key":"4325_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"key":"4325_CR76","unstructured":"Nadunolimab combined with gemcitabine, nab-paclitaxel shows promising efficacy in patients with pancreatic cancer. GI Oncology Now. 2025."},{"issue":"6","key":"4325_CR77","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","volume":"140","author":"CA Dinarello","year":"2010","unstructured":"Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140(6):935\u201350.","journal-title":"Cell"},{"key":"4325_CR78","doi-asserted-by":"crossref","unstructured":"Fan Z, Xiao Y, Du Y, Zhang Y, Zhou W. Pancreatic cancer subtyping - the keystone of precision treatment: updates from multi-omics. Nat Rev Gastroenterol Hepatol. 2025;22(5):312\u201328.","DOI":"10.3389\/fimmu.2025.1563725"},{"issue":"9255","key":"4325_CR79","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539\u201345.","journal-title":"Lancet"},{"issue":"3","key":"4325_CR80","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418\u201329.","journal-title":"Cancer Cell"},{"issue":"2","key":"4325_CR81","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/2159-8290.CD-24-0760","volume":"15","author":"H Singhal","year":"2025","unstructured":"Singhal A, Zhao X, Wall P, So E, Calderini G, Partin A, et al. The hallmarks of predictive oncology. Cancer Discov. 2025;15(2):245\u201362.","journal-title":"Cancer Discov"},{"issue":"5","key":"4325_CR82","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"8","key":"4325_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081170","volume":"11","author":"L Jin","year":"2021","unstructured":"Jin L, Kim HS, Shi J. Neutrophil in the pancreatic tumor microenvironment. Biomolecules. 2021;11(8):1170.","journal-title":"Biomolecules"},{"issue":"1","key":"4325_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06711-z","volume":"23","author":"J Ge","year":"2025","unstructured":"Ge J, Cai J, Zhang G, Li D, Tao L. Multi-omics integration and machine learning uncover molecular basal-like subtype of pancreatic cancer and implicate A2ML1 in promoting tumor epithelial-mesenchymal transition. J Transl Med. 2025;23(1):741.","journal-title":"J Transl Med"},{"key":"4325_CR85","unstructured":"DaSilva B, Neugut AI, Fojo T, Bates SE. Advances in pancreatic cancer: 2025 ASCO highlights and novel therapies. Nat Rev Gastroenterol Hepatol. 2025;22(8):512\u201328."},{"key":"4325_CR86","unstructured":"Niu N, Shen X, Wang Z, Chen Y, Weng Y, Yu F, et al. Tumor cell-intrinsic metabolic reprogramming induces the hallmarks of EMT in pancreatic cancer. Nat Commun. 2023;14(1):229."},{"key":"4325_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/OA-24-00050","volume":"1","author":"JM Finan","year":"2024","unstructured":"Finan JM, Guo Y, Goodyear SM, Brody JR. Challenges and opportunities in targeting the complex pancreatic tumor microenvironment. JCO Oncol Adv. 2024;1:e2400050.","journal-title":"JCO Oncol Adv"},{"issue":"1","key":"4325_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023;36(1):2129884.","journal-title":"J Invest Surg"},{"issue":"11","key":"4325_CR89","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","volume":"23","author":"Y Toi","year":"2018","unstructured":"Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with Nivolumab. Oncologist. 2018;23(11):1358\u201365.","journal-title":"Oncologist"},{"key":"4325_CR90","doi-asserted-by":"crossref","unstructured":"Ju Y, Xu D, Liao MM, Sun Y, Bao WD, Yao F. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024;8(1):208.","DOI":"10.1038\/s41698-024-00681-z"},{"issue":"18","key":"4325_CR91","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-356","volume":"10","author":"J Yin","year":"2022","unstructured":"Yin J, Shen S, Shi Q. Challenges, opportunities, and innovative statistical designs for precision oncology trials. Ann Transl Med. 2022;10(18):1038.","journal-title":"Ann Transl Med"},{"issue":"20","key":"4325_CR92","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1001\/jama.283.20.2701","volume":"283","author":"EJ Emanuel","year":"2000","unstructured":"Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283(20):2701\u201311.","journal-title":"JAMA"},{"issue":"2","key":"4325_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1950","volume":"16","author":"Y Cao","year":"2024","unstructured":"Cao Y, Meng F, Cai T, Gao L, Lee J, Solomevich SO, et al. Nanoparticle drug delivery systems responsive to tumor microenvironment: promising alternatives in the treatment of triple-negative breast cancer. WIREs Nanomed Nanobiotechnol. 2024;16(2):e1950.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"4325_CR94","doi-asserted-by":"crossref","unstructured":"Sharma S, Singh R, Kant S, Mishra MK. Integrating AI\/ML and multi-omics approaches to investigate the role of TNFRSF10A\/TRAILR1 and its potential targets in pancreatic cancer. Comput Biol Med. 2025;178:108789.","DOI":"10.1016\/j.compbiomed.2025.110432"},{"issue":"19","key":"4325_CR95","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1039\/D5NA00513B","volume":"7","author":"L Peng","year":"2025","unstructured":"Peng L, Liang Y, Guo X, Zhang Q, Gao Z, Kong X, et al. Nanomedicine breakthroughs overcoming pancreatic cancer drug resistance through precision nano-interventions. Nanoscale Adv. 2025;7(19):5888\u2013904.","journal-title":"Nanoscale Adv"},{"key":"4325_CR96","unstructured":"Zhu Q, Yu C, Chen Y, Luo W, Li M, Zou J, et al. Dual mRNA nanoparticles strategy for enhanced pancreatic cancer immunotherapy via neoantigen targeting. Nat Biotechnol. 2025;43(3):312\u201321."},{"issue":"10","key":"4325_CR97","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11864-025-01352-2","volume":"26","author":"C Peng","year":"2025","unstructured":"Peng C, Oberstein PE. Emerging therapeutic approaches to pancreatic adenocarcinoma: advances and future directions. Curr Treat Options Oncol. 2025;26(10):841\u201365.","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"4325_CR98","first-page":"245","volume":"70","author":"CL Rock","year":"2020","unstructured":"Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, Patel AV, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin. 2020;70(4):245\u201371.","journal-title":"CA Cancer J Clin"},{"key":"4325_CR99","doi-asserted-by":"crossref","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2018;6(2):112\u201321.","DOI":"10.1158\/2326-6066.CIR-13-0170"},{"issue":"10","key":"4325_CR100","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S1470-2045(21)00488-5","volume":"22","author":"R Rahman","year":"2021","unstructured":"Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MC, et al. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021;22(10):e456\u201365.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4325_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040836","volume":"13","author":"M Mejza","year":"2025","unstructured":"Mejza M, Bajer A, Wanibuchi S, Ma\u0142ecka-Wojciesko E. Can AI be useful in the early detection of pancreatic cancer in patients with new-onset diabetes? Biomedicines. 2025;13(4):836.","journal-title":"Biomedicines"},{"issue":"8","key":"4325_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06930-0","volume":"15","author":"H Wu","year":"2024","unstructured":"Wu H, Fu M, Wu M, Cao Z, Zhang Q, Liu Z. Emerging mechanisms and promising approaches in pancreatic cancer metabolism. Cell Death Dis. 2024;15(8):553.","journal-title":"Cell Death Dis"},{"issue":"6","key":"4325_CR103","first-page":"1123","volume":"75","author":"T Kamisawa","year":"2025","unstructured":"Kamisawa T, Goel A. Advances in pancreatic cancer early diagnosis, prevention, and treatment. CA Cancer J Clin. 2025;75(6):1123\u201345.","journal-title":"CA Cancer J Clin"},{"key":"4325_CR104","doi-asserted-by":"crossref","unstructured":"Aslam A, Hamid H, Fatima E, Pervaiz S, Arif M, Irshad H, et al. Inflammatory biomarkers in the pathogenesis of pancreatic cancer. World J Gastroenterol. 2025;31(10):1093\u2013105.","DOI":"10.5306\/wjco.v16.i10.109385"},{"key":"4325_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314918","volume":"23","author":"J Frenay","year":"2022","unstructured":"Frenay J, Bellaye PS, Oudot A, Helbling A, Petitot C, Ferrand C, et al. IL-1RAP, a key therapeutic target in cancer. Int J Mol Sci. 2022;23:14918.","journal-title":"Int J Mol Sci"},{"key":"4325_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100789","author":"K Herremans","year":"2022","unstructured":"Herremans K, Szymkiewicz D, Riner A, Bohan R, Tushoski G, Davidson A, et al. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Neoplasia. 2022. https:\/\/doi.org\/10.1016\/j.neo.2022.100789.","journal-title":"Neoplasia"},{"issue":"7637","key":"4325_CR107","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"key":"4325_CR108","unstructured":"Hanahan D. How the hallmarks of cancer reshaped the field of cancer research. Abcam Stories. 2025."},{"issue":"8008","key":"4325_CR109","first-page":"456","volume":"628","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. 2025;628(8008):456\u201362.","journal-title":"Nature"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04325-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:02:25Z","timestamp":1790164945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04325-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":109,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4325"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04325-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":5,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}